

# Nanostructured lipid carriers as semisolid topical delivery formulations for diflucortolone valerate.

Seham Elkheshen, Hussein Ammar, AZZA AHMED MOHAMED MAHMOUD, Fatma S. Abdel-Salam

## Abstract

**Context:** Topical treatment of skin disease needs to be strategic to ensure high drug concentration in the skin with minimum systemic absorption.

**Objective:** The aim of this study was to produce semisolid nanostructured lipid carrier (NLC) formulations, for topical delivery of the corticosteroid drug, diflucortolone valerate (DFV), with minimum systemic absorption.

**Method:** NLC formulations were developed using a high shear homogenization eq o d k p g f " y k v j " u q p k e c v k q p . " w u k p i " R t g e k t q n Ì " C V Q 5 " q t " V t k u v g e t k p Ì " c u " v j g " u q n k f " n k r k f . " Capryol Ì " q t " k u q r t q r { n " o { t k u v c v g " c u " v j g " n k s w k f " n k r k f " c p f " R q n q z c o g t Ì " 4 0 7 as surfactant. The present study addresses the influence of different formulations composition as solid lipid, liquid lipid types and concentrations on the physicochemical properties and drug release profile from NLCs.

**Results and discussion:** DFV-loaded NLC formulations possessed average particle size ranging from 160.40 p o " v q " 7 4 3 . 7 p o " y k v j " p c t t q y " r q n { f k u r g t u k v { " k p f g z 0 " V j g " encapsulation efficiency was improved by adding the lipid-based surfactants \* N e d t c u q n Ì " c p f " N e d t c h k n Ì " O 1 9 4 4 C S ) to reach 68%. The drug release from the investigated NLC formulations showed a prolonged release up to 12 j 0 " V j g " dermatopharmacokinetic study revealed an improvement in drug deposition in the skin with the optimized DFV-loaded NLC formulation, in contrast to a commercial formulation.

**Conclusion:** NLC provides a promising nanocarrier system that work as reservoir for targeting topical delivery of DFV.

*Journal of Liposome and Research 2017, January*